TY - JOUR
T1 - Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
AU - Parham, Johnathon Seth
AU - Goldberg, Anne Carol
N1 - Funding Information:
Dr. Goldberg reports grants from Sanofi, IONIS, Amarin, and Amgen; grants and personal fees from Regeneron and Novartis; personal fees from Merck; personal fees and non-financial support from Esperion; and personal fees from Akcea, outside the submitted work. Dr. Goldberg also reports honoraria and travel for speaking at National Lipid Association meetings and honoraria as the Chief Science Officer of the National Lipid Association.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/8
Y1 - 2022/8
N2 - Purpose of Review: There have been recent developments of novel therapeutic agents for lipid lowering. This article reviews treatment concepts for two of the newest lipid-lowering medications. Recent Findings: Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis. This oral medication is a prodrug and requires activation by enzymes present in hepatocytes but absent in the skeletal muscle. Clinical trials demonstrated additive benefit with statin therapy, and it was well tolerated in statin-intolerant populations. Inclisiran uses RNA interference to prevent translation of PCSK9 mRNA. Due to its stability, it can be given as an injection every 6 months and produces consistent, durable, and potent cholesterol lowering. Summary: Bempedoic acid and inclisiran represent new avenues of treatment for the prevention and treatment of cardiovascular disease. This will allow for more comprehensive care by addressing challenges with medication adherence, such as adverse effects to prior medications as well as ease of dosing.
AB - Purpose of Review: There have been recent developments of novel therapeutic agents for lipid lowering. This article reviews treatment concepts for two of the newest lipid-lowering medications. Recent Findings: Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis. This oral medication is a prodrug and requires activation by enzymes present in hepatocytes but absent in the skeletal muscle. Clinical trials demonstrated additive benefit with statin therapy, and it was well tolerated in statin-intolerant populations. Inclisiran uses RNA interference to prevent translation of PCSK9 mRNA. Due to its stability, it can be given as an injection every 6 months and produces consistent, durable, and potent cholesterol lowering. Summary: Bempedoic acid and inclisiran represent new avenues of treatment for the prevention and treatment of cardiovascular disease. This will allow for more comprehensive care by addressing challenges with medication adherence, such as adverse effects to prior medications as well as ease of dosing.
KW - ATP citrate lyase
KW - Bempedoic acid
KW - Inclisiran
KW - ORION
KW - RNA interference
KW - Statin intolerance
UR - http://www.scopus.com/inward/record.url?scp=85131448181&partnerID=8YFLogxK
U2 - 10.1007/s11883-022-01036-4
DO - 10.1007/s11883-022-01036-4
M3 - Review article
C2 - 35666408
AN - SCOPUS:85131448181
SN - 1523-3804
VL - 24
SP - 619
EP - 625
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
IS - 8
ER -